<unk>  is widely considered as the<unk>  virus strain of choice for clinical investigation because of its high safety profile.<unk>  has been administered to numerous animal species including monkeys, mice, swine, sheep, cattle, horses, and elephants, with no local or systemic adverse effects. Over 120,000 humans have been safely and successfully<unk> ted against smallpox with<unk>  by intradermal, subcutaneous, or intramuscular injections. Currently, the use of<unk>  as a recombinant HIV vaccine <unk> -B) is being tested in approximately 300 volunteers in several Phase I studies conducted by the International AIDS Vaccine Initiative. Studies in mice and nonhuman primates have further demonstrated the safety of<unk>  under conditions of immune suppression. Compared to replicating<unk>  viruses,<unk>  provides similar or higher levels of recombinant gene expression even in non-permissive cells. Recently,<unk> tion with smallpox vaccine (a<unk>  virus related to<unk>  has been shown, on rare occasions, to cause heart problems in people who received it: heart inflammation (myocarditis), inflammation of the membrane covering the heart (pericarditis), and a combination of these two problems (myopericarditis). A few cases of cardiac chest pain (angina) and heart attack have also been reported following smallpox<unk> tion. It is not known at this time if smallpox<unk> tion causes angina or heart attacks.<unk>  is an attenuated<unk>  virus and does not replicate in the human body as efficiently as<unk> . However, whether or not<unk>  can induce the same side effects as<unk>  is not known at this time.
Modified vaccinia Ankara
Pandemrix
Oncolytic adenovirus
Civet SARS-CoV
Limestone Canyon virus
EuCorVac-19
Oncophage
EpiVacCorona